Research Type: Assessment

Interventions of interest: Simeprevir (Olysio®, Janssen Products, LP) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) Ledipasvir/sofosbuvir (Harvoni®, Gilead Sciences, Inc.) Daclatasvir (Daklinza™, Bristol-Myers Squibb Company) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) Paritaprevir/ritonavir/ombitasvir + dasabuvir with ribavirin (Viekira Pak™, AbbVie, Inc.) Simeprevir (Olysio®, Janssen Products, LP)+ pegylated interferon and ribavirin Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) + ribavirin […]

Interventions of interest: Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.)Simeprevir (Olysio®, Janssen Products, LP) Chronic hepatitis C is a common infection that is a major cause of chronic liver disease, liver failure, and hepatocellular carcinoma (HCC), and it is the leading indication for liver transplantation in the Western world. Prior to 2011, the combination of pegylated interferon […]

Interventions of Interest: tisagenlecleucel (KymriahTM , Novartis) axicabtagene ciloleucel (YescartaTM, Kite Pharma) ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. The policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit there will be changes needed in future pricing, payment, and […]

Interventions of Interest: ICER developed a report assessing the comparative clinical effectiveness and value of certain non-pharmacologic, non-invasive interventions for chronic low back and neck pain. The report was the subject of a October 19, 2017 meeting of the California Technology Assessment Forum. Evidence from the report suggested safe and effective treatments include acupuncture, cognitive […]

Interventions of interest: Erenumab (Aimovig®, Amgen/Novartis) Fremanezumab (Ajovy®, Teva) Galcanezumab (Emgality®, Eli Lilly) Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or […]

Interventions of interest, July 2014 review: OnabotulinumtoxinA (Botox®, Allergan, Inc) Transcutaneous electrical nerve stimulation (Cefaly®, Cefaly Technology) Single pulse transcranial magnetic stimulation (SpringTMS™, eNeura Inc.) Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe […]

Interventions of Interest: Carfilzomib (Kyprolis®, Onyx) Daratumumab (Darzalex®, Janssen Bitoech) Elotuzumab (Empliciti®, Bristol MeyersSquibb) Ixazomib (Ninlaro®, Takeda) Panobinostat (Farydak®, Novartis Pharmaceuticals Corp.) Pomalidomide (Pomalyst®, Celgene) Multiple myeloma is a cancer of the blood in which the bone marrow produces a high number of cancerous plasma cells. The excessive growth of plasma cells can cause bone […]

2017 Review: Relapsing-Remitting MS and Primary Progressive MS Interventions of Interest: Injectable Agents Daclizumab (Zinbryta®, Biogen/AbbVie) Glatiramer acetate (Copaxone®, Teva) Glatiramer acetate (Glatopa®, Sandoz (Novartis)) Interferon beta-1a (Avonex®, Biogen) Interferon beta-1b (Betaseron®, Bayer) Interferon beta-1b (Extavia®, Novartis) Interferon beta-1a (Rebif®, EMD Serono) Peginterferon beta-1a (Plegridy®, Biogen) Oral Agents Dimethyl fumarate (Tecfidera®, Biogen) Fingolimod (Gilenya®, Novartis) […]

2019 Review: Secondary Progressive MS Intervention of Interest: Siponimod (MAYZENT®, Novartis) Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system.Relapsing-remitting MS (RRMS) is the most common disease course and is characterizedby periods of worsening neurologic symptoms (“relapses”) followed by partial or completerecovery. Incomplete recovery from relapses may contribute to worsening neurologic function […]

Intervention of interest: Cervical spinal fusion We completed a Technology Assessment of cervical spinal fusion for degenerative disc disease in advance of the public meeting of the Washington State Health Technology Assessment Program’s Clinical Committee. Date of review: March 2013 For questions or additional information, please contact info@icer.org Final Documents Below you will find the […]